INALIMAREV (CEA, MUC-1, VACCINIA VIRUS)
drugOn this page
Summary
Inalimarev (Cea, Muc-1, Vaccinia Virus) (CHEMBL2108609) is a phase-3 clinical-stage vaccine component; indicated across 5 conditions including breast neoplasm and adenocarcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- Indications: 5 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108609 |
| Name | INALIMAREV (CEA, MUC-1, VACCINIA VIRUS) |
| Type | Vaccine component |
| Max phase | 3 |
Also known as: Inalimarev (cea, muc-1, vaccinia virus), INALIMAREV (CEA, MUC-1, VACCINIA VIRUS)
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| adenocarcinoma | 1 | MONDO:0004970 | EFO:0000228 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.